Literature DB >> 7923178

Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.

M V Carriero1, P Franco, S Del Vecchio, O Massa, G Botti, G D'Aiuto, M P Stoppelli, M Salvatore.   

Abstract

Current evidence regarding the regulation of urokinase-dependent extracellular proteolysis indicates that plasminogen activation is a surface-associated process. We have compared the histological localization of urokinase plasminogen activator (uPA) and urokinase plasminogen activator receptor (uPAR) in breast cancer sections using a panel of monoclonal antibodies. First, the ability of six different anti-uPA monoclonal antibodies to recognize pro-uPA, uPA, and in vitro-formed complexes of uPA with either soluble uPAR or with plasminogen activator inhibitor type 1 was compared. Then the reactivity of the anti-uPAR antibodies was tested, and the occurrence of an uPA receptor of about M(r) 55,000 in samples from breast carcinoma was assessed by immunoprecipitating the uPA receptor from an in vitro 125I-labeled tumor extract. Immunocytochemical data from adjacent sections of 10 tumor specimens showed that antibodies recognizing free and bound uPA mostly stain the cytoplasm and the membrane of epithelial tumor cells in confined areas of the tumor and some fibroblast-like stromal cells. Acid pretreatment of tumor sections, which removes receptor-bound uPA, causes a strong reduction of the immunocytochemical reactivity of epithelial tumor cells, whereas staining of fibroblast-like cells is not considerably affected. Consistent with these results, epithelial tumor cells were mostly unreactive to anti-uPAR antibodies unless pretreated with acidic buffer, whereas fibroblast-like stromal cells showed a faint but acid-resistant staining with all anti-uPARs. In conclusion, these results show that occupied uPA receptors are definitely present on the membrane of epithelial tumor cells and suggest the occurrence of uPA-uPAR-dependent proteolytic activity on the surface of breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923178

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Urokinase receptor-dependent and -independent p56/59(hck) activation state is a molecular switch between myelomonocytic cell motility and adherence.

Authors:  F Chiaradonna; L Fontana; C Iavarone; M V Carriero; G Scholz; M V Barone; M P Stoppelli
Journal:  EMBO J       Date:  1999-06-01       Impact factor: 11.598

2.  Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.

Authors:  T Luther; V Magdolen; S Albrecht; M Kasper; C Riemer; H Kessler; H Graeff; M Müller; M Schmitt
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

3.  Modulation of cellular migration and survival by c-Myc through the downregulation of urokinase (uPA) and uPA receptor.

Authors:  Daniela Alfano; Giuseppina Votta; Almut Schulze; Julian Downward; Mario Caputi; Maria Patrizia Stoppelli; Ingram Iaccarino
Journal:  Mol Cell Biol       Date:  2010-02-01       Impact factor: 4.272

4.  Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas.

Authors:  B Mann; M Gelos; A Siedow; M L Hanski; A Gratchev; M Ilyas; W F Bodmer; M P Moyer; E O Riecken; H J Buhr; C Hanski
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

5.  The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.

Authors:  Minji Jo; Shinako Takimoto; Valerie Montel; Steven L Gonias
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

6.  Involvement of the soluble urokinase receptor in chondrosarcoma cell mobilization.

Authors:  Katia Bifulco; Immacolata Longanesi-Cattani; Maria Teresa Masucci; Annarosaria De Chiara; Flavio Fazioli; Gioconda Di Carluccio; Giuseppe Pirozzi; Michele Gallo; Antonello La Rocca; Gaetano Apice; Gaetano Rocco; Maria Vincenza Carriero
Journal:  Sarcoma       Date:  2010-12-30

7.  Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility.

Authors:  P Franco; C Iaccarino; F Chiaradonna; A Brandazza; C Iavarone; M R Mastronicola; M L Nolli; M P Stoppelli
Journal:  J Cell Biol       Date:  1997-05-05       Impact factor: 10.539

8.  Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy.

Authors:  W Yu; J Kim; L Ossowski
Journal:  J Cell Biol       Date:  1997-05-05       Impact factor: 10.539

9.  Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.

Authors:  D Cantero; H Friess; J Deflorin; A Zimmermann; M A Bründler; E Riesle; M Korc; M W Büchler
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.

Authors:  S Kennedy; M J Duffy; C Duggan; C Barnes; R Rafferty; M D Kramer
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.